Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

IMpower131: Improvement in OS for Stage IV NSCLC+High-PD-L1 Expression

Key clinical point: High PD-L1 expression was associated with a clinically meaningful improvement in OS in patients treated with atezolizumab + chemotherapy vs. chemotherapy alone.

Major finding: Median OS in patients with high PD-L1 expression treated with atezolizumab + chemotherapy vs. chemotherapy alone was 23.4 vs. 10.2 months; HR, 0.48.

Study details: The randomized phase 3 IMpower131 study of 1,021 patients.

Disclosures: Dr. Cappuzzo reported having no disclosures.

Citation:

Cappuzzo F et al. WCLC 2019, Abstract OA14.02.